HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 458 participants.

Also called NCT07379190

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 458 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07379190
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07379190. Randomized; single masking; primary purpose treatment. Start 2026-06-22 (actual); primary completion 2029-02-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)
Condition
Stroke, Acute
Condition
Stroke, Ischemic
Condition
Cerebral Infarction
Intervention (Drug)
Tirofiban
Intervention (Drug)
dual antiplatelet therapy
Lead sponsor
Weifang Medical University (class: other)
Collaborator
Linyi People's Hospital (class: other)
Collaborator
Qianfoshan Hospital (class: other)

Record details

Record id
cardio:ct-nct07379190
Content hash
dc181cda97eaab9b0614877570d938c5b738719f4d98cf37d535b14cb07b9df0